ArticleInfluenza and other respiratory viruses2026
Global Epidemiology of Human Adenoviruses, 2016-2024: A Pre- and Post-COVID-19 Analysis of Circulation Patterns and Epidemic Timing.
Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Global Patterns of Human Rhinovirus Activity and Epidemic Duration, 2016-2025: Before, During, and After the COVID-19 Pandemic.Pathogens (Basel, Switzerland) · 2026Article
- Risk factors for hospitalization in pediatric patients with human adenovirus infection and changes in epidemiological and clinical characteristics before and after the COVID-19 pandemic in China: a multicenter retrospective study.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman adenoviruses (HAdV) circulate globally, but their seasonal patterns remain poorly defined. We aimed to characterize the timing, amplitude, and duration of HAdV epidemics worldwide and to compare patterns before and after the COVID-19 pandemic.
methodsVirological surveillance data on HAdV were obtained from the WHO FluNet database: data from 65 countries were analyzed to estimate epidemic peak timing, amplitude, and duration across the Northern and Southern Hemispheres and the intertropical belt, comparing prepandemic (2016-2019) with postpandemic (2021-2024) periods. To ensure robustness, analyses were restricted to country-seasons with ≥ 30 reporting weeks.
resultsFrom 2016 to 2024, 65 countries reported roughly 148,000 HAdV detections across 335 country-seasons; 46% of seasons had ≥ 50 detections. In the 20 countries with sufficient data for seasonality analyses, median epidemic duration was 31 weeks (range 5-42) and median peak amplitude 70% (40%-98%). Peak timing followed latitude: June-July in Southern Hemisphere, November-December in high-latitude Northern countries, March-April in lower latitude. After COVID-19, several countries showed marked timing shifts, with concurrent changes in amplitude.
conclusionsAfter the onset of the COVID-19 pandemic, the usual seasonal patterns of HAdV were altered, with pronounced shifts in peak timing across settings and latitudes. These results underscore the need for strong, ongoing, type-specific surveillance to guide public health strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.